Ibrutinib(Imbruvica)

Ibrutinib is a prescription drug targeting Bruton's tyrosine kinase (BTK). It was first approved by the U.S. FDA in November 2013 for the treatment of mantle cell lymphoma (MCL). It must be used strictly under medical supervision.

Target of Action

Bruton's tyrosine kinase (BTK)

Dosage and Administration

Route and frequency of ibrutinib administration: Oral, once daily.

The dosage of ibrutinib should be adjusted according to the patient's actual condition; specific adjustments require consultation with a physician and adherence to medical advice.

Recommended reading: Dosage and administration of ibrutinib

Side Effects

Common side effects: Diarrhea, etc.

Serious side effects: Bleeding, infection, cardiac problems, etc.

Reference article: Side effects of ibrutinib

Use in Special Populations

Pregnancy: Effective contraception should be used during treatment with ibrutinib and for 1 month after the last dose.

Breastfeeding: Do not breastfeed during treatment with ibrutinib and for 1 week after the last dose.

Daily Precautions

1. Instruct patients to take ibrutinib as prescribed and to try to take it at the same time each day. If a dose is missed, it should be taken as soon as remembered on that day, and the regular dosing schedule should be resumed the next day. Advise patients not to take a double dose on the same day to make up for a missed dose.

2. Instruct patients or caregivers to read and follow the instructions for use for proper preparation, administration, storage, and disposal of ibrutinib oral suspension.

3. Instruct patients to swallow ibrutinib capsules or tablets with a glass of water; do not open, break, or chew the capsules, nor cut, crush, or chew the tablets.

from FDA，2024.05